Spinal muscular atrophy associated with central nervous system anomalyNews & Research
4 curated articles for Spinal muscular atrophy associated with central nervous system anomaly — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Ther Adv Rare Dis Dec 1, 2026
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.
Why it matters: Recent peer-reviewed research relevant to rare disease diagnosis or treatment.
- Mol Ther Nucleic Acids Jun 16, 2026
The post-pandemic pivot: mRNA therapeutics enter the chronic rare disease arena
Published in Mol Ther Nucleic Acids. Giangrande PH et al.
Why it matters: Recent peer-reviewed research relevant to rare disease diagnosis or treatment.
- Expert Opin Drug Discov Mar 26, 2026
The impact of antisense oligonucleotide (ASO) therapeutics on the future of rare disease drug discovery
Published in Expert Opin Drug Discov. Ruchi R et al.
Why it matters: Recent peer-reviewed research relevant to rare disease diagnosis or treatment.
- NotableEMA Mar 10, 2026
EMA Grants Conditional Approval for Novel SMA Therapy
EMA granted conditional authorization to a new oral therapy for spinal muscular atrophy.
Why it matters: More treatment options mean better outcomes. Competition drives innovation.
More on Spinal muscular atrophy associated with central nervous system anomaly
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.